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ABSTRACT  
Background: Over the last decades, gene therapy has emerged as a pioneering therapeutic approach 
to treat or prevent several diseases. Among the explored strategies, the short-term silencing of 
protein coding genes mediated by siRNAs has a good therapeutic potential in a clinical setting.  
Material & Methods: However, the widespread use of siRNA will require the development of 
clinically suitable, safe and effective vehicles with the ability to complex and deliver siRNA into target 
cells with minimal toxicity. Lately, dendrimers have gained considerable attention as non-viral 
vectors in nucleic acid delivery due to their unique structural characteristics (globular, well defined 
and highly branched structure, multivalency, low polydispersity and tunable nanosize), along with 
their relevant capacity to complex and protect nucleic acids in compact nanostructures, which can be 
functionalized with targeting moieties in order to get cell specificity.  
Conclusion: Here, we present an overview of the state-of-the-art of the most significant and recent 
advances on the use of dendrimers as siRNA delivery vectors, with particular focus on the in vivo 
applications. We will cover the use of different dendrimers, distinct administration routes, toxicity is-
sues, as well as the target tissue or disease, highlighting the potential of dendrimers as nanocarriers 
for therapeutic and biomedical applications. 
Keywords: Dendrimers, RNAi, siRNA, Gene therapy, In vivo, Nanomedicine, Nanoparticles, 
Biodistribution. 
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1. INTRODUCTION 
1.1. RNA Interference (RNAi) 
In 1998, an unforeseen gene-silencing event in nematodes [1], later called RNA interference (RNAi), 
was discovered. Further investigations confirmed that a similar response also existed in mammalian 
cells [2]. Briefly, RNAi is a post-transcriptional regulatory mechanism that consists of the cleavage, 
by an endonuclease called Dicer [3], of endogenous long double stranded RNA (dsRNA) molecules 
into small interfering RNAs of about 21–23 nucleotides that are incorporated into the RNA-Induced 
Silencing Complex (RISC). After, RNA helicases unwind the double-stranded siRNA and the antisense 
strand guides RISC to the complementary messenger RNA (mRNA) for degradation. RNAi can be 
mimicked by synthetic RNA molecules, such as micro RNA (miRNA), short hairpin RNA (shRNA) and 
small interference RNA (siRNA). The latter mediates gene silencing by inducing sequence-specific 
cleavage of targeted mRNA in a catalytic process [4-6] (Fig. 1). 
Quickly, it was appreciated the potential of RNAi-based therapies for down-regulating abnormal 
gene expression or mutated proteins involved in some human diseases that are not targetable by 
conventional drugs. Among the strategies for turning off protein expression, RNAi mediated by 
synthetic siRNAs has a good potential in a clinical setting for the exploration of new therapeutics. In 
fact, several studies have already stressed the potency of siRNA-based strategies in knocking down 
the expression of specific targets in vivo for the treatment of different diseases [7-10], and many pro-
posed therapies have completed phase I clinical trials, while others have already progressed into 
more advanced evaluation stages [11-13]. 
1.2. Advantages of siRNA Therapeutics 
siRNA can be categorized into conventional, sticky and Dicer substrate siRNA. Conventional siRNA 
is synthetic dsRNA molecule bearing 19-25 base pairs and two dTdT overhangs at the 3′-ends, which 
is designed to mimic the Dicer cleavage product and, therefore, directly enter RISC for triggering the 
RNAi mechanism [14]. Different from conventional, siRNA with short complementary An/Tn (n = 5–
8) overhangs, (instead of dTdT overhangs), named sticky siRNA, can be used, which considerably 
increases gene silencing efficiency. In addition to sticky siRNA, competent Dicer substrate siRNA 
(dsiRNA) of 25–30 nucleotides can be up to 100-fold more potent than conventional 21-mer duplex 
siRNA when targeted to the same sequence location. This dsiRNA bears an asymmetric blunt end 
and an over-hang at the 3′-end that can be optimally processed by Dicer, hence yielding higher and 
more durable RNAi effect. 
Among the different mechanisms to silence protein expression, siRNAs area very good choice as it is 
easy to dis-cover unmodified siRNAs that work with high potency. Compared to antisense 
oligonucleotides (ASOs), siRNAs have two strands, which simplifies their delivery and make siRNAs 
more resistant to nuclease degradation [15-17]. In addition, siRNAs show a more potent and 
prolonged therapeutic effect, thanks to the mentioned catalytic mechanism. Regarding dsRNAs,the 
antisense strand of siRNA is completely complementary to the mRNA target and has higher target 
recognition and binding compared to the other RNA molecules which are only partially 
complementary to the target mRNA [18, 19]. Moreover, the total understanding of the methodology 
for siRNA synthesis enables preparation of a siRNA that selectively shuts off a targeted gene. In fact, 
specific siRNAs are now commercially available to silence almost any gene and in various different 
organisms. Important to notice that the down-regulation using siRNAs is transient. This may be 
adequate for some purposes where a temporary effect is needed. In situations requiring a persistent 
effect, repeated administrations are necessary. 
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Due to the high power and lower off-target interaction of siRNA among all the antisense molecules, 
the use of siRNA has been considered the most promising tool being applied to personalized 
medicine [20, 21]. 
1.3. siRNA: Barriers, Challenges and Delivery Vectors 
Despite the great advances achieved during the last years on the understanding and harnessing of 
the RNAi-mediated gene silencing mechanisms, some aspects are yet to be improved in order to 
translate RNAi-based therapeutics into the clinics [22-24]. For instance, few studies reported non-
specific effects triggered by siRNA-based therapeutics, as the mentioned off-target silencing 
(although low) and activation of the interferon system [25-29]. The recognition of this unintended 
gene modulation has led to the improved design of siRNA sequences by the use of appropriate 
algorithms, the establishment of several rules for siRNA design and the introduction of chemical 
modifications into the nucleic acid (NA) structure, which ultimately lead to minimal off-target activity 
[30]. 
Nevertheless, the main challenge is related to the siRNA transport and delivery. Due to its large 
molecular weight (∼14 kDa in average) and polyanionic nature (negative phosphate groups), naked 
siRNA does not freely cross the cell membrane. Also, naked siRNA can be rapidly degraded by 
endonucleases when administrated and has a very short life in circulation. Therefore, it is now 
commonly accepted that the widespread use of siRNA therapeutics will require the use of clinically 
suitable, safe and effective delivery vehicles with the ability to protect naked siRNA, surpass the 
different extra- and intracellular barriers and efficiently deliver it into cells with minimal toxicity [31-
36]. The extra- and intracellular barriers and the corresponding challenges in the vector-mediated 
siRNA delivery include: a) protect siRNA against degradation by endonucleases present in the extra- 
and intra-cellular milieu, b) avoid renal clearance, particularly relevant in the case of systemic 
administration, c) delivery to the desired site of action and avoid non-specific delivery, d) pro-mote 
cellular internalization, e) favor endosomal escape, f) siRNA release from the vector and access to the 
cytoplasmic and to the RNAi machinery to permit an effective gene silencing process, and g) avoid 
vector intra- and extracellular accumulation by ineffective clearance after accomplishing their 
biological function (i.e. release the siRNA cargo). Additionally, the delivery vector must avoid 
unspecific binding to serum proteins, preventing aggregation and recognition by the complement 
system. 
Two classes of vehicles for siRNA are clearly distinguishable: viral and non-viral based vectors [37-39]. 
Even though viral based vectors have been extensively studied, showing high transfection efficiency 
rates, the adverse effects such as mutagenesis and immunogenicity are important obstacles still to 
overcome [40-43] which have limited their use in vivo. Furthermore, the low-scale production and 
storage difficulties [43] remain crucial limitations that raise concerns for its translation to the clinic. 
These facts have encouraged the development of non-viral cationic vehicles for siRNA delivery [39]. 
Electrostatic interactions between negatively charged siRNA and cationic polymers or 
macromolecules are the basis, in the great majority of cases, for the non-viral vector-mediated siRNA 
delivery. Most of the siRNA carriers tested so far have been mainly based on cationic systems 
previously developed for the delivery of plasmid DNA (pDNA) such as liposomes, lipids, cell 
penetrating peptides, natural and synthetic polymers and, more recently, dendrimers. However, 
fundamental differences between pDNA and siRNA molecules regarding size, morphology, flexibility 
and charge, can result in a less efficient interaction and lower protection of the latter [44]. Thus, the 
cationic vectors used for gene delivery do not necessarily result in optimal vectors for this small 
double-stranded NA [45-47]. Consequently, design and optimization of cationic vectors for the 
delivery of siRNA are required [47]. 
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2. DENDRIMERS 
In 1978, Voëgtle et al. synthesized a new class of multiarmed molecules (“cascade molecules”) [48]. 
The further increase in the complexity of these branched molecules by Denkewalter, Tomalia, 
Newkome, Frechet and colleagues led to larger structures/architectures, then coined as “den-
drimers” [49-52]. Dendrimers comprise: a) a central core with at least two reactive groups, b) 
repeating units linked to the central core and distributed/arranged in concentric layers named 
“generations” (G), and c) high number of terminal functional groups on their surface (Fig. 2a). This 
“treelike” structure is depicted by the word dendrimer (from Greek: dendron = tree and meros = part), 
which relates to the distinctive organization of their branched blocks. 
Soon, it was shown that dendrimers, in their cationic form, had something special to offer also as 
non-viral vectors in the gene therapy field, due to their capacity to complex and protect NAs in 
compact nanostructures (Fig. 2b) [53]. Moreover, their exclusive structural characteristics: globular, 
well-defined and highly branched structure, low polydispersity, tunable size and the possibility of 
controlled multifunctionalization (due to the presence of chemical handles on the dendritic periphery 
– multivalency), further allow a specific, fine and precise design of smart dendritic carriers for the NA 
delivery field. 
Dendrimers are synthesized mainly by two different iterative synthetic approaches: divergent [48, 
50, 51] or convergent [52], which allow their accurate design. In the divergent route, introduced by 
Tomalia, Newkome, and Voëgtle, dendrimers grow layer-by-layer from the core towards the 
periphery. The core molecule reacts with monomeric molecules (repeating unit) containing one 
reactive and at least two inactive branched sites, yielding the first-generation dendrimer (G1). Then, 
the surface of this G1 is activated for reaction with more repeating units. This process is repeated 
several times until the dendrimer of the desired generation and, therefore, size is formed. On the 
other hand, the convergent approach introduced by Fréchet et al. consists of the synthesis of 
branched individual dendrons, which are finally linked with a multifunctional core. The divergent 
methodology is susceptible to defective monomeric molecule assembly due to the higher number of 
reactions performed simultaneously, and thus, purification is usually required after each step [54]. 
Consequently, the probability of byproduct formation boosts with the generation, rendering lower 
over-all yields. Conversely, in the convergent synthesis only a limited number of groups are active per 
reaction, therefore, the probability of structural flaws is lower [54]. However, one disadvantage of 
the latter is its low ability to grow dendrimers until higher generations due to the steric hindrance 
between dendrons in the last step, although the selection of a suitable core (size and multivalency) 
can help to reduce these steric hindrances [54]. 
Finally, it is worth mentioning that new user- and environmentally-friendly synthetic approaches with 
higher reaction efficiency and step number reduction, such as “Lego” [55] and “click” [56] chemistry, 
and other accelerated and orthogonal synthesis strategies [57, 58], have been reported to overcome 
the drawbacks and the tedious purification intensive iterative processes of the previously mentioned 
classical strategies. 
3. DESIGNING DENDRIMERS FOR siRNA DELIVERY 
Cationic dendrimers represent particularly attractive class of non-viral vehicles for siRNA, since they 
are able to complex and protect this NA in compact nanostructures, coined “dendriplexes” 
(dendrimer-NA complexes) (Fig. 2b), There-fore, they contribute to surpass the previously 
mentioned extra- and intracellular barriers, towards an efficient delivery of exogenous therapeutic 
siRNA into cells. 
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The development and optimization of highly efficient and rapid synthetic approaches together with 
the design of novel orthogonal building blocks have allowed the synthesis of an ample range of 
different dendritic compounds and families with monodisperse nanosizes and great number of 
functional end groups, what also allows attaching different ligands in a controllable manner, leading 
to optimized dendritic nanocarriers. Probably, the dendritic structures most extensively investigated 
for siRNA delivery have been the poly(amidoamine)(PAMAM) [59], poly(propylene imine) (PPI) [60] 
and poly(L-lysine)-based (PLL) [61, 62] dendrimers (all commercially available), as well as carbosilane 
[63]and triazine [47] dendrimers. Even commercial gene transfection reagents such as PolyFect®, 
SuperFect® and PrioFect® based on PAMAM dendrimers initially developed for DNA delivery, have 
also been shown to efficiently mediate siRNA delivery [64, 65]. 
The primary interaction between cationic dendrimers and siRNA is electrostatic. Consequently, 
dendriplex stability and NA delivery profile usually improve with the dendritic generation [53, 66-68]. 
Nevertheless, it has also been observed that higher generations do not always lead to higher 
transfection efficiencies [60, 69]. This could be explained since dendrimers of lower generation may 
interact with NAs more efficiently than the higher generations as a result of their more flexible 
structure [70]. 
Despite the charge neutralization during the condensation process, when the molar ratio between 
the cationic groups from the dendrimer and the phosphate groups from the NA is above 1, the 
complexes preserve an excess of positive charge on their surfaces, which can result in cellular 
toxicity. Therefore, it is important to assess not only the toxicity of the free used cationic dendrimers, 
but also the one that may be elicited by the dendriplexes. The latter will be more important in the 
short-term, i.e. during transport, whereas free dendrimer toxicity may have a long-term effect, after 
NA delivery upon dendriplex disassembly. 
Although the internal dendrimer structure plays a significant role in determining the biological 
performance of these structures [71], the characteristics of their surface groups will predominantly 
determine pharmacokinetics and biocompatibility [72, 73]. In fact, cationic dendrimers will interact 
more strongly with the negatively charged surface of the cell membranes than anionic or neutral 
ones, and therefore they will be more cytotoxic [72, 74]. It seems clear that higher generation 
dendrimers, besides less biocompatible, will be more toxic because of the higher number of positive 
charges. Therefore, it could be concluded that cationic dendrimers toxicity is concentration and 
generation dependent [75, 76]. But contradictory data can be found in the literature regarding in vivo 
tests. Some studies show that PAMAM and PPI dendrimers, especially at low generations, are not as 
toxic as initially described [77-81]. However, others have reported toxicity profiles for the same 
dendrimers [82-84]. It should be noted that in vivo cytotoxicity will also depend on the dose and 
administration route [72]. Therefore, dendrimer characteristics (chemistry, size and charge – the last 
two ones closely related to generation) will also be important in the choice of the administration 
route and, consequently, on the in vivo biodistribution [72, 85-87]. These issues will be further 
discussed in detail in the following sections. 
Because of this controversial toxicity related to cationic dendrimers, much effort has been put into 
decrease /improve/optimize their cytotoxicity profile by surface engineering. For instance, 
acetylation of PAMAM dendrimers to reduce the number of primary amines [88] or also the use of 
hydroxyl-terminated PAMAM G4 dendrimers with quaternized internal amines [89] are some of the 
investigated strategies to improve biocompatibility. However, in this regard, the most common 
approach for masking the dendrimers’ charge and improving their solubility and biocompatibility, 
while increasing their circulation time in the blood stream, is to tether chains of poly(ethylene glycol) 
(PEG) to the dendritic backbone (PEGylation) [90] (Fig. 2). Moreover, other promising 
antibiofouling/non-fouling polymers have emerged as possible alternatives to PEG, such as 
zwitterionic polymers [91, 92], poly(2-oxazoline)s [91, 93, 94], poly peptoids [91], polycarbonates 
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[95], among others. Although there are already a few reports in which some of these alternative 
polymers are attached to dendritic structures [92, 94], further studies are expected to test their 
favorable properties when linked to dendrimers. 
Besides this, the possibility of precise chemical multi-decoration of dendrimers allows decreasing 
their unfavorable properties, such as the mentioned cytotoxicity, while improving the gene silencing 
effect, favoring the design of effective dendrimer-based siRNA nanocarriers. The main modification 
strategies of the dendrimers being explored to optimize their vectorization capability include: 
1) The tethering to the dendrimer surface of different molecules, such as amino acids [47, 96-98], 
cyclodextrins [99-103] and hydrophobic moieties [47, 88, 104-107] in an optimized percentage and 
form. These modifications aim to increase the dendriplex stability and siRNA protection capability, 
as well as to enable the parent dendrimer to traverse the cell membrane, disrupt the endosomal 
mem-brane and/or facilitate endosomal escape – one critical challenge when talking about non-viral 
vector mediated siRNA delivery [108]. 
2) Adjustment of the core structure [66, 68, 109-115] to enhance siRNA transfection efficiency. For 
instance, PAMAM dendrimers were studied with different types of core: a flexible core consisting on 
triethanolamine (TEA) [68, 113, 114], and a rigid poly(phenylene vinylene) (PPV) core [112]. Also, the 
focal point of dendrons can be used for linking moieties, mainly hydrophobic molecules, with the 
same aim of improving gene silencing [116, 117].Fig. (2). Schematic representation of: a) a dendrimer 
with attached chains of poly(ethylene glycol) (PEG) and a target molecule, b) siRNA/dendrimer 
complex (dendriplex). 
3) Finally, the conjugation of several ligands and target molecules (Fig. 2), such as peptides and 
proteins, tailored to attain an efficient and site-specific (cells and tissues) siRNA delivery is also an 
attractive strategy [62, 103, 118-123]. 
In addition to these dendrimer modifications, the suitable choice of the generation number 
(according to the dendritic family), will also have a significant impact on the enhancement of the 
transfection efficiency 47, 68]. 
Despite all these improvements on the design of dendrimers to act as vectors for siRNA delivery, the 
non-biodegradability under physiological conditions of the most commonly used dendritic structures 
in the NA delivery field remains a weak point that scientists need to further address [54, 72, 124, 125]. 
After accomplishing their biological function – release the siRNA cargo – non-biodegradable 
dendrimers can also lead to cytotoxicity induced by the accumulation of non-degradable synthetic 
materials inside cells/tissues [86, 124]. Therefore, the ideal delivery vehicle should be biodegradable 
to prevent bioaccumulation and subsequent cytotoxicity [86, 124-126]. Moreover, the dendrimers’ 
biodegradability can also contribute to the efficient release of the transported NA [125, 127], and 
consequently yield higher RNAi. 
In the following sections, some of the most significant and recent advances in the use of dendrimers 
as siRNA vectors in in vivo applications are revised. We cover the use of different dendrimers, distinct 
administration routes, toxicity issues, as well as the targeting of a specific tissue or disease, 
highlighting the caveats and potential of dendrimers as nanocarriers for therapeutic applications. 
4. IN VIVO APPLICATIONS 
The administration of siRNA dendriplexes to organisms requires preliminary extensive studies in the 
test tube and also with cells in culture. The strategies tested in vivo are, therefore, the result of 
innumerous iterative improvements previously tested in vitro. The delivery of siRNA mediated by 
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dendrimers has been applied to date in different paradigms, with different aims and using different 
strategies. These studies in vivo using dendrimers to carry siRNA will be analyzed regarding its 
success rate, efficiency, toxicity and organ/cell specificity. 
4.1. Dendrimer Types Applied In Vivo 
Among the different dendrimers explored for siRNA delivery (PAMAM, PPI, PLL, carbosilane, and 
triazine), PAMAM has been the most widely used and studied vector in in vivo applications (Table 1). 
A large variety of modifications have been performed and tested in order to overcome the known 
obstacles faced in the complex in vivo environment.  
In 2009, an approach using polyvalent dendrimer-bearing magnetic nanoparticles (“dendriworm”), 
which allow to locate in vivo the nanoparticles by imaging techniques, were used to carry siRNA to 
the most common and most aggressive brain cancer - a glioblastoma induced in mice [111], the most 
common and most aggressive brain cancer. For dendriworm development, cystamine core G4 
PAMAM dendrimers were reduced yielding thiol dendrons. Then, amine-modified, cross-linked 
strings of spherical iron oxide nanoparticles coated with a biocompatible polymer (Dextran), named 
“nanoworms” [128], were prepared. Finally, reduced dendrons and nanoworms were conjugated 
using the heterobifuctional linker succinimidyl 3-(2-pyridyldithio) propionate (SPDP). The effects of 
siRNA delivered by den-driworms to the brain parenchyma were studied in healthy and brain tumor 
tissue, after intracranial infusion with an osmotic pump for a long period of time (3 and 7 days). These 
dendriworms showed improved proton sponge effect and enhanced endosomal escape efficiency 
when compared to dendrimers or nanoworms, resulting therefore in a better siRNA silencing. 
Another group has reported promising results using a flexible TEA-core PAMAM dendrimer for 
delivering a cocktail of anti-HIV-1 Dicer substrate siRNAs in a humanized mouse model [113]. 
These dendriplexes suppressed viral infection by several orders of magnitude compared to free 
siRNA, which constitutes a big step in the treatment of HIV infection. 
Liu and colleagues developed arginine-terminated dendrimers with the aim of combining the 
appropriate properties of the TEA-core PAMAM dendrimer in siRNA delivery and the cell-
penetrating advantages of the arginine-rich motif, which enhances cell membrane penetration. This 
proved to be effective in delivering siRNAs, leading to potent gene silencing in vivo [129]. 
An efficient strategy, also using a TEA-core PAMAM dendrimer, to deliver heat shock transcription 
factor 27 (Hsp27) sticky siRNA to prostate cancer cells was explored by Peng’s group. It produced 
potent gene silencing of Hsp27, which in turn lead to a notable anticancer effect [114]. The same team 
also reported a lipid/dendrimer hybrid bearing a hydrophobic long alkyl chain and a low generation 
hydrophilic PAMAM dendron was used in a prostate cancer mouse model [130]. This system 
displayed the advantageous delivery features of both lipid and polymer vectors. Hsp27 siRNA was 
delivered locally to the tumor and a high rate of success for gene silencing and anticancer activity was 
obtained. 
As previously mentioned, other types of dendrimers appropriately modified for in vivo applications, 
have also been successfully employed with relevance (Table 1). Taratula et al. proposed a strategy 
using PPI dendrimers in which siRNA nanoparticles were caged with a dithiol containing cross-linker 
molecules and coated with PEG polymer [121]. These modifications provided lateral and steric 
stability to withstand the aggressive environment in the blood. Reduction of the intramolecular 
disulfide bond in the cytoplasm triggered the release of siRNA in cancer cells with success. The 
targeting delivery approach was obtained by conjugation to the dendriplexes of the luteinizing 
hormone-releasing hormone peptide, which directed the nanoparticles to the lung cancer cells.  
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Serramia et al. reported the delivery of siRNA to the brain using a carbosilane dendrimer carrier [131]. 
After cell culture studies with these dendriplexes, their ability to cross the blood−brain barrier (BBB) 
was investigated and it was found that they efficiently reached the brain after a retro-orbital injection 
administration. 
Very recently, 1,500 modular dendrimers based on 2-(acryloyloxy)ethyl methacrylate (AEMA), with 
chemically diversified cores, peripheries and generations modified with ester bonds, were 
synthesized by a sequential modular synthesis strategy [87]. From these, 50 top lead G1 to G4 
dendrimers were tested in vivo for siRNA delivery. After selecting five dendrimers that led to 
knockdown with high potency, toxicity studies were performed and three dendrimers were excluded 
due to significant toxicity, which was shown by weight loss. The remaining two best dendrimers were 
tested in an aggressive liver cancer model, where the one with a lineal pentamine core and octane-1-
thiol surface modified, was the best tolerated and led to a significant high siRNA accumulation in the 
tumor. 
4.2. Route of Administration 
Therapeutics can be introduced into the body by various routes such as intravenous (i.v.), 
intraperitoneal (i.p.), intra-muscular, subcutaneous, among others. [132]. The route of administration 
has a profound effect on the accessibility of molecules/structures to their respective target site, as 
well as the speed and the efficiency with which the therapeutic will act. Consequently, it will have a 
profound impact on the in vivo performance of the administered system. When choosing the route 
of administration for the nanoparticle/dendriplex, one has to equate various aspects: a) the 
accessibility to the target site, b) the least invasive technique that still is effective in delivering 
therapeutic amounts of the selected agent, c) the volumes and frequency of administration, d) 
possible side effects, e) stability of the dendriplex after delivery, f) clearance through the body, and 
g) toxicity. 
The most traditional route for the delivery of dendrimers and dendriplexes is the i.v. route [123 and 
Table 1]. With this systemic administration, it is common to find dendriplexes in the liver as well as in 
the spleen (though not so often studied). This accumulation is explained since these are organs of the 
reticuloendothelial system responsible for the clearance of foreign materials by macrophage uptake. 
It is also common to find dendriplexes in the kidneys. Renal excretion of dendrimers after systemic 
administration is known and therefore it is expected that dendrimers are present in this organ. For 
example, the fate of free cationic PAMAM dendrimers (G3 and G4) and anionic PAMAM dendrimer 
(G 2.5, 3.5 and 5.5) after i.v. administration has been studied, to find that these materials accumulate 
in the liver and also that they are cleared from the blood via the kidney though with different 
clearance rates [146]. Moreover, it was also observed that after i.p. injection, most of the 
administrated dendrimers were transferred into the blood within an hour and exhibited a similar 
clearance pattern to the results found after i.v. injection. One of the main problems in systemic 
administration of cationic macromolecules is vector aggregation in the presence of serum that in the 
context of siRNA delivery mediated by dendrimers can result in nanoparticle disintegration, siRNA 
release and degradation. As mentioned before, PEGylation of the nanoparticle structures can 
prevent particle aggregation and increase their stability in serum. Therefore, this is a very common 
dendrimer and dendriplex modification for in vivo purposes. To overcome some of the limitations 
associated with systemic administration, local delivery of dendriplexes can be performed which 
increases site direct activity and minimizes systemic toxicity. This type of administration is found in 
various cancer studies (Table 1) where for example TEA-core PAMAM dendrimers complexed with 
siRNA have been directly administered to the tumor site [115]. Also regarding cancer, a useful 
strategy in brain is the use of convection enhanced delivery (CED) though it is very invasive due to 
the intracerebral injection [111]. A heart local injection has also been effective in improving cardiac 
function in a mice model of cardiovascular disease [137]. 
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The choice of the route of administration of the dendriplexes sometimes requires adjustments in its 
formulation. Such was the case in the study performed with radiolabeled [32P]-siRNA/PAMAM 
dendriplexes, where intranasal administration was chosen in order to reach the brain [135]. The 
dendriplexes were administered within an in situ forming mucoadhesive gel so as to increase the 
retention time of the dendriplexes in the nose mucosa and potentiate the rate of success after 
administration. 
When repeated administrations are required due to the siRNA transient effect, more invasive routes 
of administration like the intracranial or intramyocardial are not a viable option. 
Therefore, the choice for the route of administration has to take into account different factors, such 
as the purpose of the delivery, the dendrimer characteristics and the frequency of administration, 
which in turn will dictate the effectiveness of the procedure. 
4.3. Biodistribution 
As seen so far, dendrimers can be better suited for delivering siRNA to a specific organ, cell 
population or a diseased site depending on its composition, generation, size, surface functional 
groups and modifications. All of these characteristics will affect their biodistribution and, 
consequently, the RNAi efficiency. As an example, Anderson’s group, employed a combinatorial 
approach, with PAMAM and PPI dendrimers modified with epoxide-terminated alkyl chains of 
increasing length to deliver siRNA to endothelial lung cells [107]. It was observed that the optimized 
formulations that included cholesterol, improved endothelial cell uptake of siRNA in vivo, 
consequently increasing tunica interna endothelial cell kinase (Tie2) lung knockdown. It was 
reasoned that when coupled with cholesterol, more serum proteins as for example albumin, were 
able to adsorb to the dendriplex, which in turn enhanced endothelial cell uptake. Moreover, the 
endothelium of other organs was also examined, but the knockdown effect was most potent in the 
lung because of thedendriplexes higher avidity for lung endothelial cells. These findings may have 
applications in the treatment of dysfunctional lung endothelium. Again, the same team synthetized 
a library of different dendrimers to deliver siRNA preferentially to: a) endothelial cells in the liver, or 
b) endothelial cells and hepatocytes, or c) endothelial cells, hepatocytes, and liver tumor cells in 
vivo[106]. The differential tropism of the dendriplexes to different cells within the liver was influenced 
by the carbon chain length of the alkyl epoxide and the ratio of cholesterol used in its formulation. 
Therefore, besides performing modifications to direct the dendriplexes to a specific organ, it is also 
possible to target the dendriplexes to distinct cell sub-populations within the same organ by tuning 
its formulation. Regarding cancer research, previous studies suggested that vascularized tumors 
experience increased uptake of nanoparticles due to the their leaky vasculature and consequent 
enhanced permeation and retention (EPR) effect [147]. This phenomenon is the rationale for the 
higher accumulation of dendriplexes after systemic administration in such tumors. To increase the 
amount of dendriplexes reaching the tumor (or in fact any target organ) after an i.v. administration, 
it is important to extend its circulating time in blood, which can be attained by, for example, 
PEGylation as previously mentioned [90]. Also, the size is an important parameter to take into 
account. Addition of successive layers (generations) gradually increases molecular size and amplifies 
the number of surface groups present, which in principle will allow to increase proportionally the 
amount of bound siRNA. But the size will also impact on the dendrimer biodistribution, as was seen 
using a 3D multicellular tumor spheroid (MCTS) model where smaller PAMAM dendrimers not only 
diffused more rapidly in the extracellular matrix, but also efficiently penetrated to the MCTS core 
compared to their larger counterparts [148].  
In the field of nanoparticle delivery to the central nervous system (CNS), there are additional major 
obstacles to the success of the procedure. The BBB prevents most small molecules and nearly all 
macromolecules from entering the CNS [149]. Current strategies used for dendriplex delivery to the 
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brain include invasive and local delivery. Direct injection is mostly appropriate for local activity, as for 
example in brain tumors when there are no metastases, but it is not adequate when the pathological 
impact is widespread and the invasiveness nature of the technique surpasses its benefits. Therefore, 
systemic delivery is a possible option to reach the brain when the BBB is compromised such as in 
stroke. However, this method of delivery also leads to nanoparticles delivery to other organs besides 
the brain, which might result in unintended effects. To overcome this lack of specificity, tageting 
moieties can be added to the surface of the dendrimer as mentioned in previous sections. This should 
lead to a certain preferential localization. As an example, transferrin addition to a G3 PPI dendrimer 
increased significantly the dendrimer BBB crossing that in turn increased the amount in the brain 
[150]. Many reports also exist in cancer research where, for instance, folic acid is added to the 
dendrimer resulting in the targeting to the tumor [101]. 
To conclude, dendriplexes biodistribution depends not only on the administration site, but also on 
the dendrimer itself i.e. its size, composition and post-synthesis surface modifications (PEGylation, 
targeting molecules, etc.). 
4.4. In Vivo Toxicity 
Cell culture studies have shown that cationic dendrimer and dendriplex cytotoxicity is mainly 
attributed to the interaction of their surface positive charge with negatively charged biological 
membranes. The interaction of dendrimers with biological membranes can result in membrane 
disruption via “nanohole” formation, membrane thinning and erosion, which lead to necrosis/non-
apoptotic cell death [151]. Several reports have carefully described the influence of dendrimer 
chemistry, size and charge on biological membranes integrity [146]. Moreover, recent works propose 
that, besides membrane destabilization, toxicity may also come up from impaired oxidative 
metabolism resulting from mitochondrial dysfunction [152] and changes in endogenous gene 
expression [153] that ultimately lead to apoptotic cell death. 
To minimize the possible toxicity, different strategies in the synthesis and modification of the 
cationic dendrimers have been performed, as described above. However, to date there is no 
“standard” strategy in the dendrimers synthesis/modification in order to overcome a possible toxicity 
after in vivo administration. Some authors claim that the use of lower generation dendrimers may 
also diminish the likelihood of immune system activation and inflammatory response associated with 
the use of higher generation dendrimers [151]. But there is no consensus on this subject. For in-
stance, Okuda and colleagues concluded that G6-PAMAM dendrimers did not induce any measurable 
hepatic damages [154], while a lower generation G4-PAMAM dendrimer even induced anti-
inflammatory activity [78]. Regarding surface chemical engineering, toxicity profiles are not always 
improved by functionalization. As an example, Albertazzi and co-workers explored the effect of un-
modified and C12-acetylated G4-PAMAM dendrimers in the CNS and they found in vivo toxicity only 
for the modified dendrimer [155]. However, this could be surpassed if modifications are tuned 
regarding aliphatic chain length and percentage of functionalization. Conflicting data can arise be-
cause each dendrimer will have its own requirements for synthesis and/or modification in order to 
overcome toxicity and, as commented in the previous sections, the needed modifications have to be 
carried out in an optimized form. Also, each intended purpose or function attributed to the dendrimer 
will dictate its structure, the concentration or amount needed and, concomitantly, this will affect 
toxicity. Thus, each dendrimer has to be evaluated in the proper context and taking into 
consideration the efficiency in which it reaches a certain tissue. So, in one situation the dendrimer 
may not be toxic while in another it can constitute a problem if for instance it accumulates in 
increased amounts. 
Regarding dendriplexes, it is obvious that their toxicity depends on the toxicity of the parent 
dendrimer. However, after complexation with the NA, the toxicity, for both systems (parent 
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dendrimer and dendriplex) should be equally assessed. Nevertheless, most of the reports show 
similar profiles, as recently reported by Chen et al., who used self-assembled small amphiphilic 
dendrons into nanosized supramolecular dendrimer micelles resembling high generation dendrimers 
[156]. These supramolecular structures showed no toxicity either alone or when complexed with the 
siRNA, and the purpose of effective gene silencing was achieved.It is intuitive to accept that the dose 
and frequency of administration are also parameters to take into account when considering toxicity 
after dendriplex administration [151]. A too high dose or multiple administrations with short intervals 
can induce, for example, a lysosomal storage problem if the dendrimers do not degrade and 
accumulate in this organelle [157]. A balance should then exist between the lowest amounts of 
administered dendriplexes with the highest possible effect elicited by them. 
The best practices in this area of research indicate that toxicity in in vitro cell culture should be 
assessed before in vivo toxicity studies are performed, in order to prove the safety of any 
nanoparticle. But, even though numerous in vitro studies have shown severe undesirable effects, 
recent reports indicate that these cannot be always extrapolated to in vivo settings [158]. So, 
dendrimer and dendriplex toxicity evaluation in vivo is essential and can be performed in many ways, 
as for example monitoring weight loss, organ histopathology, hemolysis (red blood cell morphology), 
alterations in transaminases, alterations in urea nitrogen levels, behavioral studies, lactate 
dehydrogenase activity in serum, interferon response or inflammatory response.  
Watanabe and colleagues showed that delivery of apolipoprotein B (ApoB) - specific siRNA with G6 
PLL dendrimers led to knockdown of ApoB in healthy mice liver without hepatotoxicity [143]. The 
potential toxicity was assessed by measuring the serum levels of aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT), which are two enzymes located in liver cells that leak into the 
circulation when liver cells are injured.  
Another study intended to deliver siRNA to the lung, showed that, at high doses, the G1 
dendrimer−lipid derivatives of PAMAM and PPI dendrimers used did not cause chronic increases in 
pro-inflammatory cytokines and animals did not suffer weight loss due to toxicity [107]. 
Different kinds of carbosilane-based dendriplexes have shown good toxicity profiles in peripheral 
blood mononuclear cells and erythrocytes over extended periods of time [159]. 
 Fortunately, in general, surface and/or core modified cationic dendrimers as well as their 
siRNA/dendriplexes display a good toxicity profile, do not show major histopathological changes nor 
exacerbate the inflammatory response (Table 1), which is significant for further translational studies. 
4.5. Therapeutic and Biomedical Applications 
siRNAs can be therapeutically applied as antiviral or anticancer agents, in CNS therapeutics, in 
inflammation or cardiovascular therapeutics, among others [160]. Dendritic structures make 
excellent delivery systems for siRNA delivery and their ability to target specific cells and to release 
the NA in a controlled manner without toxicity was already proven, as highlighted in this review. 
Reports in different areas have emerged as for example in cancer, HIV-1 infection, neurodegenerative 
diseases such as Familial Amyloidotic Polyneuropathy (FAP) and in stroke. 
For cancer applications, siRNA delivery with dendrimers has been extensively studied in animal 
cancer models (Table 1). Some studies apply the dendriplexes directly to tumors [114, 115, 129, 130], 
others have performed systemic ad-ministration of dendriplexes functionalized with targeting 
moieties directed to cancer cells [101, 121], and also both approaches - intratumoral administration 
with cancer targeting moieties - have also been reported by Wei et al. [161]. In this last study, by using 
gold nanostar-based platform modified with PAMAM dendrimers, the authors proposed an 
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interesting diagnosis application for tumor computed tomography imaging. Additionally, a 
therapeutic approach combining both photothermal and gene therapy was also proposed in vivo. 
Other promising dual-delivery studies using siRNA and an anticancer drug, both complexed with the 
dendrimer can also be found in the literature, which significantly potentiated the antitumor effect of 
the drug [115, 140, 142]. This can occur by sensitizing the cancer cells to the chemotherapy due to co-
application of specific siRNAs responsible for regulating chemoresistance [162]. 
The previously mentioned study by Zhou and colleagues [113], in HIV-1 infected humanized mice, 
which suppressed infection after dendriplexes delivery, represents a promising strategy for the 
treatment of HIV. 
In FAP, a hereditary disease caused by the liver expression of mutated transthyretin (TTR), Hayashi 
et al. used a lactosylated dendrimer (G3) conjugated with α-cyclodextrin as a novel hepatocyte-
specific siRNA carrier for TTR [102, 145]. The dendriplex had a potent in vivo gene silencing effect in 
the liver without toxicity, constituting therefore an-other therapeutic tool for FAP treatment.  
In brain ischemia studies, Kim and colleagues used arginine-modified PAMAM dendrimers (G4) to 
deliver siRNA against High-mobility group box 1 (HMGB1) to the post-ischemic brain with success 
[133]. siRNA was detected 1 h after delivery and maintained for at least 12 h and, most significantly, 
neuroprotection was observed.  
Based on the above, the siRNA/dendrimers-based nanomedicine shows very good prospects in 
biomedical application of various natures, and further studies accomplished in vivo, for future 
translation constitutes a worth-while goal. 
CONCLUSION 
Among the approaches explored in gene therapy, the down-regulation of protein expression 
mediated by siRNAs is one of the most promising strategies. However, its success will be intimately 
related with the development of efficient vectors. Although there have been many advances in this 
field, the design of an effective and non-toxic vehicle that allows the delivery of siRNA in the desired 
tissue or organ needs further improvements so as to widespread the therapeutic application of RNAi. 
In this context, dendrimers arose as promising candidates due to their globular, well defined, very 
branched and multifunctionalizable structure, their low polydispersity, as well as their particular 
capacity to complex and protect siRNA in compact nanostructures. 
Many efforts have been made to develop and optimize dendritic structures for siRNA delivery. The 
possibility of multifunctionalization has allowed a great variety of chemical 
decorations/modifications, especially the ones introduced onto the dendrimer periphery, with the 
aim of decreasing cytotoxicity, while improving biocompatibility. Moreover, target molecules can be 
linked in a controllable manner in order to get tissue-or cell specificity. Regardless of the cost and 
regulatory obstacles associated, the targeted approach continues being of great interest for 
scientists, especially for in vivo applications, since it minimizes the complicated side effects besides 
maximizing the site-specificity.  
However, despite this great advance in the design of dendrimers to act as effective vectors of siRNA, 
there are some aspects/issues that still need to be improved and/or sur-passed. For instance, as 
previously mentioned, one important drawback is the bioaccumulation of the vector and possible 
subsequent toxicity after accomplishing their biological function. Because of this, more fundamental 
research should be directed to develop fully biodegradable dendrimers, whose goal not only concerns 
toxicity, but also puts forward the design of “smart” controlled delivery systems. This aims at 
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triggering and/or sustaining the release of the therapeutic siRNA via the control of the vector 
degradation profile, as is being currently explored by us and others. 
Besides optimizing the design of dendrimers for in vivo applications [163], it is important to consider 
also the pharmacokinetics so that a slower clearance and higher activity of the selected siRNA in the 
target site have to be observed. This is intimately connected to the amount and frequency of the 
doses that should be optimized and adjusted. Ultimately, it is obligatory to explore various safety 
issues in the pre-clinical scenario such as the degradability and biocompatibility. The benefits should 
always surpass the risks. 
In the future, further contributions of dendriplex mediated siRNA delivery are expected, which may 
constitute a remarkable pre-clinical landmark in nanomedicine therapeutics. Combining all the 
aforementioned characteristics in one dendritic system would be a big step forward to translate 
therapeutic siRNA-dendriplexes into a clinical reality. 
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Table 1. Description of distinct in vivo studies using dendrimers to deliver siRNA. The information 
is grouped according to the dendrimer type. Abbreviations: PAMAM: poly(amidoamine); PLL: 
Poly(L-lysine); PPI: Poly(propylene imine); PG: Poly(glycerol); TEA: Triethanolamine; PEG: 
Poly(ethylene glycol); i.v.: intravenous; i.n. intranasal; i.p.: intraperitoneal; Tie2: tunica interna 
endothelial cell kinase; HMGB1: High-mobility group box 1; HSP27: heat shock transcription 
factor 27; EGFR: Epidermal growth factor receptor; ATR1: Angiotensin II type 1 receptor; ApoB: 
Apoliprotein B, mdr1: multidrug resistance 1; PLK1: Polo-like kinase 1; BCl2: B-cell lymphoma 2; 
TTR: Transthyretin; Nef: Negative Regulatory Factor; D-siRNA: Dicer-substrate siRNA; PBMC: 
peripheral blood mononuclear cells.  
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